12.11.2013 13:30:41
|
Isis Pharmaceuticals Gets $1.5 Mln Milestone Payment From Biogen - Quick Facts
(RTTNews) - Isis Pharmaceuticals, Inc.(ISIS), Tuesday said it earned $1.5 million in milestone payments from Biogen Idec(BIIB), for the advancement of the ongoing Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy or SMA. The trial is an open-label, multiple-dose, dose-escalation pilot study in infants who have been diagnosed with Type I SMA. The study is being conducted at centers in the United States and Canada.
ISIS-SMNRx is an investigational compound designed to alter the splicing of a closely related gene (SMN2) to increase production of fully functional SMN protein. The compound received orphan drug status and fast track designation from the United States Food and Drug Administration or FDA.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu ISIS Pharmaceuticals Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu ISIS Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Biogen Inc | 131,20 | 2,66% |
|